Patents by Inventor Maria DE PIZZOL

Maria DE PIZZOL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROTROPHINS FOR USE IN THE TREATMENT OF HEARING LOSS
    Publication number: 20200155647
    Abstract: The present invention relates to the use of neurotrophins in the treatment of hearing disorders related to hearing loss using the transtympanic route of administration, in particular in the treatment of sudden deafness, blast-induced hearing loss, ototoxicity, ARHL (age related hearing loss) and noise damage. The invention further relates to the use of compositions containing neurotrophins, in particular NGF, in the treatment of hearing disorders.
    Type: Application
    Filed: May 22, 2018
    Publication date: May 21, 2020
    Inventors: Maria DE PIZZOL, Andrea ARAMINI, Anna SIRICO, Mara ZIPPOLI, Giuseppina ACERRA, Simone Luca MATTIOLI
  • Sulfonamides as GPR40- and GPR120-agonists
    Patent number: 10508090
    Abstract: The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 17, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Maria De Pizzol, Anna Sirico, Mara Zippoli, Gianluca Bianchini, Andrea Beccari, Andrea Aramini, Chiara Rossana Maria Liberati
  • SULFONAMIDES AS GPR40- AND GPR120-AGONISTS
    Publication number: 20190169142
    Abstract: The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Inventors: Maria DE PIZZOL, Anna SIRICO, Mara ZIPPOLI, Gianluca BIANCHINI, Andrea BECCARI, Andrea ARAMINI, Chiara Rossana Maria LIBERATI